HealthStream Zukünftiges Wachstum
Future Kriterienprüfungen 1/6
Für HealthStream wird ein Gewinn- und Umsatzwachstum von 10.5% bzw. 4.9% pro Jahr prognostiziert, während der Gewinn je Aktie voraussichtlich um 10.7% pro Jahr steigen soll.
Wichtige Informationen
10.5%
Wachstumsrate der Gewinne
10.68%
EPS-Wachstumsrate
| Healthcare Services Gewinnwachstum | 22.1% |
| Wachstumsrate der Einnahmen | 4.9% |
| Zukünftige Eigenkapitalrendite | n/a |
| Analystenabdeckung | Low |
| Zuletzt aktualisiert | 24 Jun 2026 |
Jüngste Aktualisierungen zum künftigen Wachstum
Analyseartikel • Nov 06
Earnings Beat: HealthStream, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
It's been a good week for HealthStream, Inc. ( NASDAQ:HSTM ) shareholders, because the company has just released its...Analyseartikel • Feb 27
HealthStream, Inc. Just Beat EPS By 5.1%: Here's What Analysts Think Will Happen Next
Shareholders might have noticed that HealthStream, Inc. ( NASDAQ:HSTM ) filed its yearly result this time last week...Recent updates
Narrativ-Update • Jun 13
HSTM: Buybacks And Updated Assumptions Will Shape Balanced Future Share Performance
Analysts have raised their price target on HealthStream by $3. They cite updated views on its fair value and revised assumptions for the discount rate, revenue growth, profit margins, and future P/E.Narrativ-Update • May 30
HSTM: AI Disruption Risks And Buybacks Will Shape Future Share Performance
Analysts have raised their fair value estimate for HealthStream from $21.00 to $24.00, citing updated views on the company’s discount rate, revenue growth, profit margins, and future P/E assumptions reflected in recent Street research. Analyst Commentary Street research around HealthStream has become more mixed, even as some firms lift price targets.Narrativ-Update • Apr 22
HSTM: AI Disruption Risks And Capital Returns Will Drive Future Share Performance
Narrative Update on HealthStream Analysts have reset their price target on HealthStream to $21 from $25, citing respectable 4Q'25 results and management's detailed response to AI-related risks. They view this as leaving the company relatively better positioned than many other SaaS peers.
Narrativ-Update • Apr 08
HSTM: AI Risk Positioning And Capital Returns Will Support Upside Potential
Analysts have reduced the fair value estimate for HealthStream from $34.00 to $30.50, citing a lower forward P/E assumption and an increased discount rate, while also referencing recent Street research that trimmed the price target to $21 and highlighted both respectable 4Q'25 results and management's case that the company is relatively well positioned against AI-related risks in SaaS. Analyst Commentary Recent Street commentary on HealthStream focuses on how the company is handling AI related risks in SaaS and what that could mean for valuation and execution.Narrativ-Update • Mar 25
HSTM: AI Disruption Risks And Capital Returns Will Shape Future Outlook
Analysts have reset their price target on HealthStream to $21, down from $25, after incorporating fresh views on AI-related risks and management's argument that the company is relatively well positioned compared with other SaaS names. Analyst Commentary Bearish analysts have trimmed expectations on HealthStream by cutting the price target to $21 from $25, while maintaining a neutral stance on the shares.Narrativ-Update • Mar 10
HSTM: AI Risks, Capital Returns And Fair Value Will Shape Outlook
Analysts have reduced their price target on HealthStream to $21 from $25, citing a recalibration of fair value, discount rate and future P/E assumptions, while also highlighting management's view that the business model remains relatively well positioned against rising AI related concerns for SaaS names. Analyst Commentary Bearish analysts are signaling a more cautious stance on HealthStream after the latest quarterly update.Narrativ-Update • Feb 24
HSTM: Dividend Hike And Buyback Will Support Future Upside Potential
Analysts have kept their $25.00 price target for HealthStream unchanged, citing only slight tweaks to assumptions around the discount rate, revenue growth, profit margin, and future P/E that together do not materially shift their overall view on the stock. What's in the News The board approved a quarterly cash dividend of US$0.035 per share, a 12.9% increase from the prior US$0.031, payable on March 20, 2026, to shareholders of record on March 9, 2026 (company announcement).Narrativ-Update • Feb 10
HSTM: Fine Tuned Assumptions Will Support Future Upside Potential
Analysts kept their fair value estimate for HealthStream at $25.00, with modest tweaks to inputs such as discount rate, revenue growth, profit margin, and future P/E assumptions. This underpins the unchanged price target and reflects only fine tuning in their models rather than a shift in overall view.Analyseartikel • Feb 07
HealthStream, Inc. (NASDAQ:HSTM) Investors Are Less Pessimistic Than Expected
HealthStream, Inc.'s ( NASDAQ:HSTM ) price-to-earnings (or "P/E") ratio of 28.8x might make it look like a sell right...Narrativ-Update • Jan 27
HSTM: Share Repurchases And Acquisition Efforts Will Drive Future Upside
Analysts now place their fair value estimate for HealthStream at US$25.00. The updated target reflects small tweaks to discount rate, revenue growth, profit margin, and future P/E assumptions in their models.Narrativ-Update • Jan 12
HSTM: Share Buybacks And M&A Activity Will Support Future Upside
Analysts have trimmed their fair value estimate for HealthStream from US$28 to about US$25. They cite updated assumptions on discount rates, revenue growth, profit margins, and a lower future P/E multiple in their refreshed models.Analyseartikel • Nov 06
Earnings Beat: HealthStream, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
It's been a good week for HealthStream, Inc. ( NASDAQ:HSTM ) shareholders, because the company has just released its...Analyseartikel • Oct 30
A Look At The Intrinsic Value Of HealthStream, Inc. (NASDAQ:HSTM)
Key Insights Using the 2 Stage Free Cash Flow to Equity, HealthStream fair value estimate is US$29.23 With US$24.60...Seeking Alpha • Jun 04
HealthStream: High-Quality Business At A Fair Price
Summary HealthStream boasts a resilient, founder-led SaaS business model with decades of profitable growth, strong balance sheet, and shareholder-friendly capital returns. Revenue is highly recurring and predictable due to long-term, non-cancelable contracts, with built-in price escalators and industry-leading products recognized by G2. Short-term headwinds include funding cuts, customer bankruptcy, and delayed revenue recognition, prompting a downward revision in 2025 guidance, but technical issues are seen as temporary. Transition to SaaS and platform offerings positions HealthStream for higher margins and future growth, with most products tied to essential, mandatory healthcare requirements. Despite strong fundamentals, the stock remains expensive on a P/E basis but appears fairly valued on a P/S basis; thus, I rated it as HOLD overall, with a small starter position reflecting my long-term confidence in the business. Read the full article on Seeking AlphaAnalyseartikel • May 23
We Discuss Why The CEO Of HealthStream, Inc. (NASDAQ:HSTM) Is Due For A Pay Rise
Key Insights HealthStream's Annual General Meeting to take place on 29th of May Total pay for CEO Bobby Frist includes...Analyseartikel • May 07
HealthStream (NASDAQ:HSTM) Is Doing The Right Things To Multiply Its Share Price
There are a few key trends to look for if we want to identify the next multi-bagger. Firstly, we'd want to identify a...Analyseartikel • Feb 27
HealthStream, Inc. Just Beat EPS By 5.1%: Here's What Analysts Think Will Happen Next
Shareholders might have noticed that HealthStream, Inc. ( NASDAQ:HSTM ) filed its yearly result this time last week...Analyseartikel • Nov 28
Should You Be Adding HealthStream (NASDAQ:HSTM) To Your Watchlist Today?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Analyseartikel • Nov 07
Returns At HealthStream (NASDAQ:HSTM) Are On The Way Up
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Typically, we'll want...
Neues Narrativ • Sep 24
Navigating Temporary Challenges, The Company Sets Its Sights On Long-term Revenue Growth And Market Expansion
Expansion into the health plan market and strong sales pipelines in key products signal potential for revenue growth and customer base diversification.Analyseartikel • Aug 08
HealthStream, Inc.'s (NASDAQ:HSTM) Shareholders Might Be Looking For Exit
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 17x, you may...Analyseartikel • Jul 17
We Ran A Stock Scan For Earnings Growth And HealthStream (NASDAQ:HSTM) Passed With Ease
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Analyseartikel • Apr 24
HealthStream, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
It's been a good week for HealthStream, Inc. ( NASDAQ:HSTM ) shareholders, because the company has just released its...Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2028 | 361 | N/A | 39 | N/A | 1 |
| 12/31/2027 | 343 | 24 | 42 | 84 | 5 |
| 12/31/2026 | 327 | 22 | 35 | 73 | 5 |
| 3/31/2026 | 312 | 20 | 33 | 63 | N/A |
| 12/31/2025 | 304 | 18 | 31 | 63 | N/A |
| 9/30/2025 | 299 | 21 | 29 | 61 | N/A |
| 6/30/2025 | 295 | 20 | 31 | 62 | N/A |
| 3/31/2025 | 292 | 19 | 35 | 64 | N/A |
| 12/31/2024 | 292 | 20 | 30 | 58 | N/A |
| 9/30/2024 | 288 | 20 | 32 | 60 | N/A |
| 6/30/2024 | 285 | 18 | 38 | 66 | N/A |
| 3/31/2024 | 283 | 18 | 37 | 64 | N/A |
| 12/31/2023 | 279 | 15 | 36 | 64 | N/A |
| 9/30/2023 | 277 | 13 | 31 | 58 | N/A |
| 6/30/2023 | 274 | 13 | 22 | 49 | N/A |
| 3/31/2023 | 270 | 12 | 24 | 51 | N/A |
| 12/31/2022 | 267 | 12 | 26 | 51 | N/A |
| 9/30/2022 | 263 | 9 | 24 | 49 | N/A |
| 6/30/2022 | 259 | 7 | 20 | 46 | N/A |
| 3/31/2022 | 259 | 6 | 19 | 44 | N/A |
| 12/31/2021 | 257 | 6 | 17 | 42 | N/A |
| 9/30/2021 | 254 | 7 | 18 | 42 | N/A |
| 6/30/2021 | 251 | 8 | 24 | 47 | N/A |
| 3/31/2021 | 247 | 9 | 28 | 49 | N/A |
| 12/31/2020 | 245 | 14 | 17 | 36 | N/A |
| 9/30/2020 | 246 | 17 | 26 | 44 | N/A |
| 6/30/2020 | 247 | 18 | 25 | 43 | N/A |
| 3/31/2020 | 250 | 17 | 30 | 56 | N/A |
| 12/31/2019 | 254 | 14 | N/A | 66 | N/A |
| 9/30/2019 | 251 | 14 | N/A | 67 | N/A |
| 6/30/2019 | 249 | 13 | N/A | 65 | N/A |
| 3/31/2019 | 242 | 14 | N/A | 51 | N/A |
| 12/31/2018 | 232 | 13 | N/A | 43 | N/A |
| 9/30/2018 | 227 | 13 | N/A | 40 | N/A |
| 6/30/2018 | 222 | 12 | N/A | 39 | N/A |
| 3/31/2018 | 218 | 11 | N/A | 39 | N/A |
| 12/31/2017 | 215 | 9 | N/A | 47 | N/A |
| 9/30/2017 | 218 | 5 | N/A | 45 | N/A |
| 6/30/2017 | 222 | 5 | N/A | 47 | N/A |
| 3/31/2017 | 224 | 4 | N/A | 35 | N/A |
| 12/31/2016 | 192 | 5 | N/A | 24 | N/A |
| 9/30/2016 | 223 | 6 | N/A | 24 | N/A |
| 6/30/2016 | 219 | 7 | N/A | 16 | N/A |
| 3/31/2016 | 216 | 7 | N/A | 32 | N/A |
| 12/31/2015 | 209 | 9 | N/A | 35 | N/A |
| 9/30/2015 | 198 | 9 | N/A | 31 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: HSTMDas prognostizierte Gewinnwachstum (10.5% pro Jahr) liegt über der Sparquote (3.5%).
Ertrag vs. Markt: HSTMDie Erträge des Unternehmens (10.5% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (18.1% pro Jahr).
Hohe Wachstumserträge: HSTMDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.
Einnahmen vs. Markt: HSTMDie Einnahmen des Unternehmens (4.9% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (12.8% pro Jahr).
Hohe Wachstumseinnahmen: HSTMDie Einnahmen des Unternehmens (4.9% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von HSTM in 3 Jahren voraussichtlich hoch sein wird
Wachstumsunternehmen entdecken
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/07/09 22:53 |
| Aktienkurs zum Tagesende | 2026/07/09 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details des Analysemodells, das zur Erstellung dieses Berichts verwendet wurde, sind auf unserer GitHub-Seite verfügbar. Außerdem haben wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf YouTube.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
HealthStream, Inc. wird von 11 Analysten beobachtet. 5 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Matthew Gillmor | Baird |
| Vincent Colicchio | Barrington Research Associates, Inc. |
| Richard Close | Canaccord Genuity |